Brief: Galderma Nemolizumab Phase II Data Show Relief For Children Moderate-To-Severe Atopic Dermatitis
15/10/2026 06:02
BRIEF-Galderma Nemolizumab Phase II Data Show Relief For Children Moderate-To-Severe Atopic Dermatitis Oct 15 (Reuters) - GALDERMA GROUP AG GALD.S:
NEMOLIZUMAB PHASE II DATA SHOW LONG-TERM SYMPTOM RELIEF FOR CHILDREN AGED 2 TO 11 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Source text: ID:nBw3pXFZVa
Further company coverage: GALD.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Galderma AG
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Brief: Galderma Group To Present Eight Posters On Injectable Aesthetics At Amwc Dubai 2026
Europe Research Roundup: AJ Bell, CMC Markets, Nestle
Press Digest: Wall Street Journal - October 15
Brief: Galderma Nemolizumab Phase II Data Show Relief For Children Moderate-To-Severe Atopic Dermatitis